Richard P Junghans
Overview
Explore the profile of Richard P Junghans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thomas A, Sumughan S, Dellacecca E, Shivde R, Lancki N, Mukhatayev Z, et al.
JCI Insight
. 2021 Nov;
6(22.
PMID: 34806651
Mutations underlying disease in tuberous sclerosis complex (TSC) give rise to tumors with biallelic mutations in TSC1 or TSC2 and hyperactive mammalian target of rapamycin complex 1 (mTORC1). Benign tumors...
2.
Mukhatayev Z, Dellacecca E, Cosgrove C, Shivde R, Jaishankar D, Pontarolo-Maag K, et al.
Front Immunol
. 2020 Dec;
11:581433.
PMID: 33335528
Vitiligo is an autoimmune skin disease characterized by melanocyte destruction. Regulatory T cells (Tregs) are greatly reduced in vitiligo skin, and replenishing peripheral skin Tregs can provide protection against depigmentation....
3.
Katz S, Moody A, Guha P, Hardaway J, Prince E, LaPorte J, et al.
J Immunother Cancer
. 2020 Aug;
8(2).
PMID: 32843493
In recent years, cell therapy technologies have resulted in impressive results in hematologic malignancies. Treatment of solid tumors with chimeric antigen receptor T-cells (CAR-T) has been less successful. Solid tumors...
4.
Cho J, Okuma A, Al-Rubaye D, Intisar E, Junghans R, Wong W
Sci Rep
. 2020 Feb;
10(1):3000.
PMID: 32060414
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
5.
Katz S, Hardaway J, Prince E, Guha P, Cunetta M, Moody A, et al.
Cancer Gene Ther
. 2019 Jun;
27(5):341-355.
PMID: 31155611
Effective chimeric antigen receptor-modified T-cell (CAR-T) therapy for liver metastases (LM) will require innovative solutions to ensure efficient delivery and minimization of systemic toxicity. We previously demonstrated the safety of...
6.
Balkhi M, Wittmann G, Xiong F, Junghans R
iScience
. 2018 Nov;
2:105-122.
PMID: 30428369
T cells infiltrate affected organs in chronic infections and malignancy, but they may fail to eradicate virus-infected cells or tumor because of exhaustion. This report describes a Yin Yang-1 (YY1)-centered...
7.
Cornetta K, Duffy L, Feldman S, Mackall C, Davila M, Curran K, et al.
Mol Ther Methods Clin Dev
. 2018 Sep;
10:371-378.
PMID: 30211249
Replication-competent retrovirus (RCR) is a safety concern for individuals treated with retroviral gene therapy. RCR detection assays are used to detect RCR in manufactured vector, transduced cell products infused into...
8.
Guha P, Gardell J, Darpolor J, Cunetta M, Lima M, Miller G, et al.
Oncogene
. 2018 Aug;
38(4):533-548.
PMID: 30158673
Immunosuppressive myeloid-derived suppressor cells (MDSC) subvert antitumor immunity and limit the efficacy of chimeric antigen receptor T cells (CAR-T). Previously, we reported that the GM-CSF/JAK2/STAT3 axis drives liver-associated MDSC (L-MDSC)...
9.
Cho J, Okuma A, Al-Rubaye D, Intisar E, Junghans R, Wong W
Sci Rep
. 2018 Mar;
8(1):3846.
PMID: 29497107
Axl is a tyrosine kinase receptor that is commonly overexpressed in many cancers. As such, Axl represents an attractive therapeutic target. The transfer of engineered T cell expressing chimeric antigen...
10.
Perreault R, Fournier C, Mattingly D, Junghans R, Talmo C
J Arthroplasty
. 2017 Aug;
32(10):2990-2994.
PMID: 28757131
Background: Tranexamic acid (TXA) reduces intraoperative blood loss and transfusions in patients undergoing total knee arthroplasty. Although numerous studies demonstrate the efficacy of intravenous and topical TXA in these patients,...